- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00136903
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation
Study Overview
Status
Conditions
Detailed Description
Protocol 260 - Participants will be randomized with equal probability to the treatment arms (2 million cells/kilogram (kg) of Prochymal® or 8 million cells/kg of Prochymal®) using a stratified block design. The stratification factor is acute GVHD grade. For the purpose of stratification, the GVHD grades are II and III-IV. Treatment with investigational agent will be administered on study Days 1 and 4. Participants will be followed for safety and efficacy until Day 28 after initiation of treatment with the investigational agent, or until withdrawal or death, whichever occurs first.
Protocol 261- This study is designed as a long-term safety follow-up of participants who take part in the preceding clinical study of Prochymal® (Protocol 260) for the treatment of acute GVHD. Participants will be enrolled in Study 261 upon completion of the preceding Study 260.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46237
- St. Francis Hospital
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Kansas City Cancer Centers - BMT
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- The Cancer Center at Hackensack University
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
New York, New York, United States, 10029
- Mt. Sinai Hospital
-
Rochester, New York, United States, 14642
- University of Rochester
-
Valhalla, New York, United States, 10595
- New York Medical College
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin, FEC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Protocol 260 Inclusion Criteria:
- Participant must be 18 to 70 years of age inclusive.
- If female and of child-bearing age, participant must be non-pregnant, not breast feeding, and use adequate contraception. Males must use adequate contraception.
- Participant must have newly diagnosed, Grade II-IV acute GVHD requiring therapy. Biopsy for confirmation of GVHD is not mandatory, but is recommended when feasible. Enrollment should not be delayed awaiting biopsy results.
- Participant must have received either full or reduced intensity myeloablative regimens followed by an allogeneic hematopoietic stem cell transplant using bone marrow, peripheral blood stem cell, or cord blood, including donor lymphocyte infusion (DLI).
Participant must have minimal renal and hepatic function as defined by:
* Calculated creatinine clearance (CLcr) of > 30 mL/min using the Cockroft-Gault equation.
- Participant must be available for all specified assessments at the study site through study Day 28.
- Participant must provide written informed consent and authorization for use and disclosure of protected health information (PHI).
Protocol 260 Exclusion Criteria:
- Participant has received previous treatment for Grade II-IV acute GVHD (except as noted in Criterion 2).
- Participant has been treated for GVHD with methylprednisolone, > 2mg/kg/day, for more than 72 hours prior to receiving Prochymal®.
- Participant has uncontrolled alcohol or substance abuse within 6 months of randomization.
- Participant has received an investigational agent (not approved by food and drug administration (FDA) for marketed use in any indication) within 30 days of randomization. Participant may not receive an investigational agent during the 28-day study period.
- Participant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant (e.g., uncontrolled infection, right heart failure, pulmonary hypertension, etc.).
- Participant has unstable arrhythmia.
- Participant is unwilling to sign consent form for the long-term follow-up study, Protocol 261.
- Participant has a known allergy to bovine or porcine products.
- Participant had received transplant for a solid tumor disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prochymal® - 2 Million cells/kg
Participants will receive Prochymal® consisting of 2 million hMSCs/kg actual body weight, intravenously (IV) on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 milligrams (mg)/kg IV or prednisone 2.5 mg/kg orally.
Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.
|
2 million hMSCs/kg actual body weight, IV on study Days 1 and 4
Other Names:
Methylprednisolone 2 mg/kg administered intravenously.
Prednisone 2.5 mg/kg administered orally.
Administered as prescribed by the caregiver.
Administered as prescribed by the caregiver.
Administered as prescribed by the caregiver.
|
Active Comparator: Prochymal® - 8 Million cells/kg
Participants will receive Prochymal® consisting of 8 million hMSCs/kg actual body weight IV on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 mg/kg IV or prednisone 2.5 mg/kg orally.
Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.
|
Methylprednisolone 2 mg/kg administered intravenously.
Prednisone 2.5 mg/kg administered orally.
Administered as prescribed by the caregiver.
Administered as prescribed by the caregiver.
Administered as prescribed by the caregiver.
8 million hMSCs/kg actual body weight IV on study Days 1 and 4
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Protocol 260 - Response by Day 28, also called Overall Response (OR). OR includes complete response (CR) and partial response (PR)
Time Frame: 28 Days
|
28 Days
|
Protocol 261-The incidence rate of different adverse events among participants treated with either dose of Prochymal® in the preceding study (Protocol No. 260).
Time Frame: 2 Years
|
2 Years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,
Time Frame: 28 Days
|
28 Days
|
Protocol 260 - Time to best response of GVHD
Time Frame: 28 Days
|
28 Days
|
Protocol 260 - Time to improvement of GVHD in one or more organs
Time Frame: 28 Days
|
28 Days
|
Protocol 261 - Survival through study day 90
Time Frame: 90 Days
|
90 Days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41. doi: 10.1016/S0140-6736(04)16104-7.
- Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002 Jan;30(1):42-8. doi: 10.1016/s0301-472x(01)00769-x.
- Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000 Aug;28(8):875-84. doi: 10.1016/s0301-472x(00)00482-3.
- Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005 May;11(5):389-98. doi: 10.1016/j.bbmt.2005.02.001.
- Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36-45. doi: 10.1080/14653240510018118.
- Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Jul;15(7):804-11. doi: 10.1016/j.bbmt.2008.03.012.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Graft vs Host Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Dermatologic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Methylprednisolone
- Prednisone
- Tacrolimus
- Mycophenolic Acid
- Cyclosporine
- Cyclosporins
- Remestemcel-l
Other Study ID Numbers
- 260-261
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graft Vs Host Disease
-
Dana-Farber Cancer InstituteBayer; Genzyme, a Sanofi CompanyCompleted
-
Rambam Health Care CampusWithdrawnFecal Microbiota Transplantation in Graft vs. Host DiseaseIsrael
-
Novartis PharmaceuticalsCompletedCorticosteroid Refractory Acute Graft vs Host DiseaseGermany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
-
Washington University School of MedicineCompletedGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
-
Shenzhen University General HospitalRecruitingGraft Vs Host DiseaseChina
-
National Cancer Institute (NCI)TerminatedGraft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host DiseaseUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedGraft Vs Host DiseaseUnited States
-
AbgenixSangstat Medical CorporationCompletedGraft Vs Host DiseaseUnited States
-
Boston Children's HospitalBristol-Myers SquibbRecruitingGraft Vs Host DiseaseUnited States
-
Christopher DvorakRecruitingGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
Clinical Trials on Prochymal® - 2 Million cells/kg
-
MetroHealth Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Terminated
-
National Institute of Allergy and Infectious Diseases...University of PittsburghRecruitingKidney Transplant | Renal Transplant RecipientsUnited States
-
Mesoblast, Inc.Juvenile Diabetes Research FoundationCompletedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent | Juvenile DiabetesUnited States
-
Mesoblast, Inc.CompletedCrohn's DiseaseUnited States, Canada, New Zealand, Australia
-
A.O. Ospedale Papa Giovanni XXIIIRegional Hospital of Bolzano; Azienda Ospedaliera San Gerardo di MonzaCompleted
-
Mesoblast, Inc.CompletedGraft Versus Host DiseaseUnited States, Italy, Australia, Canada, Switzerland, United Kingdom
-
Mesoblast, Inc.No longer availableGraft-Versus-Host DiseaseUnited States
-
The First Affiliated Hospital of Soochow UniversityFundamenta Therapeutics, Ltd.RecruitingB Cell Lymphoma | CAR | Relapsed Non-Hodgkin LymphomaChina
-
Mesoblast, Inc.No longer availableGraft vs Host Disease | Graft-Versus-Host DiseaseUnited States, Canada
-
Diskapi Teaching and Research HospitalNot yet recruitingMeniscus DisorderTurkey